Trusopt
indicated for ocular hypertension to alleviate intraocular pressure.
Strengths: 2%
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Carbonic Anhydrase Inhibitor
- Pharmacological class
Sulphonamide
- Contraindications
hypersensitivity to dorzolamide; severe renal impairment
- Minor side effects
ocular burning; stinging; bitter taste
- Moderate side effects
conjunctivitis; blurred vision; superficial punctate keratitis
- Dosage forms
Eye drops, solution
- Administration route
Ocular use
- Patient summary
indicated for ocular hypertension to alleviate intraocular pressure.
- Prescription status
POM
- Manufacturer
Merck Sharp & Dohme
- Onset Time
1–2 hours
- Duration
8–12 hours
- Storage instructions
Store below 30°C. Protect from light.
- Drug interactions
topiramate
- Age restrictions
Not recommended for infants.
- Pregnancy and breastfeeding
Pregnancy: Use with caution. Breastfeeding: Consult a physician.
Precautions and warnings
may cause stinging upon application; monitor for allergic skin reactions; contact lenses should be removed before administration
Serious side effects
urolithiasis — requires immediate medical attention; stevens-johnson syndrome — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Mechanism of action
Dorzolamide inhibits the enzyme carbonic anhydrase in the ciliary processes of the eye, decreasing the secretion of aqueous humour and effectively reducing elevated intraocular pressure associated with glaucoma.
Trusopt
indicated for ocular hypertension to alleviate intraocular pressure.
Editorial Notes
- Active ingredient(s): Dorzolamide
- Listed indication(s): Glaucoma, Ocular Hypertension